Combretastatin A4 phosphate: background and current clinical status (Q35871932)

10 August 2017

1 reference

title

Combretastatin A4 phosphate: background and current clinical status (English)

1 reference

10 August 2017

Scott L Young

1

1 reference

PubMed ID

15330748

10 August 2017

David J Chaplin

series ordinal

2

1 reference

PubMed ID

15330748

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

1 reference

10 August 2017

13

1 reference

10 August 2017

9

1 reference

10 August 2017

1171-1182

1 reference

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Factors determining the action of colchicine on tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

The biology of the combretastatins as tumour vascular targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combination of vascular targeting agents with thermal or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1171

10.1517/13543784.13.9.1171

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15330748